These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 19411636)

  • 1. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.
    Qadura M; Waters B; Burnett E; Chegeni R; Bradshaw S; Hough C; Othman M; Lillicrap D
    Blood; 2009 Jul; 114(4):871-80. PubMed ID: 19411636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
    Delignat S; Dasgupta S; André S; Navarrete AM; Kaveri SV; Bayry J; André MH; Chtourou S; Tellier Z; Lacroix-Desmazes S
    Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products.
    Jankowski W; Park Y; McGill J; Maraskovsky E; Hofmann M; Diego VP; Luu BW; Howard TE; Kellerman R; Key NS; Sauna ZE
    Blood Adv; 2019 May; 3(9):1429-1440. PubMed ID: 31053570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
    Mannucci PM; Shi Q; Bonanad S; Klamroth R
    Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.
    Peyvandi F; Cannavò A; Garagiola I; Palla R; Mannucci PM; Rosendaal FR;
    J Thromb Haemost; 2018 Jan; 16(1):39-43. PubMed ID: 29080391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of the interaction between anti-FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance.
    Grancha S; Ortiz AM; Marañón C; Hampel K; Moret A; Zimmermann B; Jorquera JI; Aznar JA
    Haemophilia; 2012 Nov; 18(6):982-9. PubMed ID: 22646163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma-derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study.
    Bravo MI; Pérez A; Raventós A; Grancha S; Jorquera JI; Butta NV; Álvarez-Román MT; Costa M; Willis T; Jiménez-Yuste V
    Haemophilia; 2022 Sep; 28(5):737-744. PubMed ID: 35654086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor VIII concentrate inhibits T helper type 2 cytokine production in vitro: relevance to inhibitor antibody formation.
    Hodge G; Han P
    Haemophilia; 2001 Sep; 7(5):490-6. PubMed ID: 11554937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
    Neufeld EJ; Sidonio RF; O'Day K; Runken MC; Meyer K; Spears J
    J Med Econ; 2018 Aug; 21(8):762-769. PubMed ID: 29681200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
    Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
    Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological activity of a new recombinant human coagulation factor VIII and its efficacy in a small animal model.
    Wu J; Zhang H; Lian T; Ding Y; Song C; Li D; Wu L; Lei T; Liang H
    Biochem Biophys Res Commun; 2023 Jan; 640():80-87. PubMed ID: 36502635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of factor VIII concentrate on leucocyte cytokine receptor expression in vitro: relevance to inhibitor formation and tolerance induction.
    Hodge G; Saxon B; Revesz T
    Haemophilia; 2006 Mar; 12(2):133-9. PubMed ID: 16476087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allergic reaction in a cohort of haemophilia A patients using plasma-derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII.
    Montalvão SA; Tucunduva AC; Siqueira LH; Sambo AL; Medina SS; Ozelo MC
    Haemophilia; 2015 Jul; 21(4):e281-5. PubMed ID: 25929310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intermediate-purity factor VIII (FVIII) concentrate on lymphocyte proliferation and apoptosis: transforming growth factor-beta is a significant immunomodulatory component of FVIII.
    Hodge G; Han P
    Br J Haematol; 2001 Nov; 115(2):376-81. PubMed ID: 11703339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors.
    Bravo MI; Da Rocha-Souto B; Grancha S; Jorquera JI
    Haemophilia; 2014 Nov; 20(6):905-11. PubMed ID: 25156825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of bleeding disorders: basic science.
    Ofosu FA; Santagostino E; Grancha S; Marco P
    Haemophilia; 2012 May; 18 Suppl 2():8-14. PubMed ID: 22530574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphatidylserine reduces immune response against human recombinant Factor VIII in Hemophilia A mice by regulation of dendritic cell function.
    Gaitonde P; Peng A; Straubinger RM; Bankert RB; Balu-Iyer SV
    Clin Immunol; 2011 Feb; 138(2):135-45. PubMed ID: 21094627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Danger signal-dependent activation of human dendritic cells by plasma-derived factor VIII products.
    Miller L; Weissmüller S; Ringler E; Crauwels P; van Zandbergen G; Seitz R; Waibler Z;
    Thromb Haemost; 2015 Aug; 114(2):268-76. PubMed ID: 25947149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII. Kogenate Japanese Clinical Study Group.
    Shima M; Sawamoto Y; Nakai H; Kamisue S; Murakami T; Morichika S; Tanaka I; Hayashi K; Yoshioka A
    Int J Hematol; 1995 Jul; 62(1):35-43. PubMed ID: 7670006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review.
    Iorio A; Halimeh S; Holzhauer S; Goldenberg N; Marchesini E; Marcucci M; Young G; Bidlingmaier C; Brandao LR; Ettingshausen CE; Gringeri A; Kenet G; Knöfler R; Kreuz W; Kurnik K; Manner D; Santagostino E; Mannucci PM; Nowak-Göttl U
    J Thromb Haemost; 2010 Jun; 8(6):1256-65. PubMed ID: 20345722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.